EUVIMEDEUVIMED entdecken
Open Access

Aerosol Delivery Efficiency With High-Flow Nasal Cannula Therapy in Neonatal, Pediatric, and Adult Nasal Upper-Airway and Lung Models

Robert M DiBlasi, Rebecca J Engberg, Jonathan Poli, Kristen E Carlin, Niko Kontoudios, P Worth Longest, Masaki Kajimoto

Respiratory Care · 2024

DOI: 10.4187/respcare.11400 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Respiratory Care, 2024. Verfasst von Robert M DiBlasi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Therapy Department, Seattle Children's Hospital, Seattle, Washington; and Center for Respiratory Biology and Therapeutics, Seattle Childr…. Hauptthemen laut MEDLINE: Aerosols, Cannula, Nebulizers and Vaporizers, Lung. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: High-flow nasal cannula (HFNC) systems employ different methods to provide aerosol to patients. This study compared delivery efficiency, particle size, and regional deposition of aerosolized bronchodilators during HFNC in neonatal, pediatric, and adult upper-airway and lung models between a proximal aerosol adapter and distal aerosol circuit chamber. METHODS: A filter was connected to the upper airway to a spontaneously breathing lung model. Albuterol was nebulized using the aerosol adapter and circuit at different clinical flow settings. The aerosol mass deposited in the upper airway and lung was quantified. Particle size was measured with a laser diffractometer. Regional deposition was assessed with a gamma camera at each nebulizer location and patient model with minimum flow settings. RESULTS: Inhaled lung doses ranged from 0.2–0.8% for neonates, 0.2–2.2% for the small child, and 0.5–5.2% for the adult models. Neonatal inhaled lung doses were not different between the aerosol circuit and adapter, but the aerosol circuit showed marginally greater lung doses in the pediatric and adult patient models. Impacted aerosols and condensation in the non-heated HFNC and aerosol delivery components contributed to the dispersion of coarse liquid droplets, high deposition (11–44%), and occlusion of the supine neonatal upper airway. In contrast, the upright pediatric and adult upper-airway models had minimal deposition (0.3–7.0%) and high fugitive losses (∼24%) from liquid droplets leaking out of the nose. The high impactive losses in the aerosol adapter (56%) were better contained than in the aerosol circuit, resulting in less cannula sputter (5% vs 22%), fewer fugitive losses (18% vs 24%), and smaller inhaled aerosols (5 µ m vs 13 µ m). CONCLUSIONS: The inhaled lung dose was low (1–5%) during HFNC. Approaches that streamline aerosol delivery are needed to provide safe and effective therapy to patients receiving aerosolized medications with this HFNC system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AerosolsCannulaNebulizers and VaporizersLungParticle SizeBronchodilator AgentsHumansInfant, NewbornAdultAdministration, InhalationChildAlbuterolModels, AnatomicDrug Delivery SystemsInfantEquipment Design

Stichwörter der Autor:innen

aerosol deliverybronchodilatorhigh-flow nasal cannulalung dosescintigraphyvibrating mesh nebulizer

Substanzen

AerosolsBronchodilator AgentsAlbuterol

Autor:innen und Institutionen

  • Respiratory Therapy Department, Seattle Children's Hospital, Seattle, Washington; and Center for Respiratory Biology and Therapeutics, Seattle Children's Research Institute, Seattle, Washington robert.diblasi@seattlechi…
  • Center for Respiratory Biology and Therapeutics, Seattle Children's Research Institute, Seattle, Washington; and Pediatric Intensive Care Unit, Seattle Children's Hospital, Seattle, Washington.
  • Center for Respiratory Biology and Therapeutics, Seattle Children's Research Institute, Seattle, Washington.
  • Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington.
  • Respiratory Therapy Department, Seattle Children's Hospital, Seattle, Washington; and Center for Respiratory Biology and Therapeutics, Seattle Children's Research Institute, Seattle, Washington.
  • Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, Virginia.

Zitieren

APA

DiBlasi, R. M., Engberg, R. J., Poli, J., Carlin, K. E., Kontoudios, N., Longest, P. W., & Kajimoto, M. (2024). Aerosol Delivery Efficiency With High-Flow Nasal Cannula Therapy in Neonatal, Pediatric, and Adult Nasal Upper-Airway and Lung Models. Respiratory Care. https://doi.org/10.4187/respcare.11400

Vancouver

DiBlasi RM, Engberg RJ, Poli J, Carlin KE, Kontoudios N, Longest PW, et al. Aerosol Delivery Efficiency With High-Flow Nasal Cannula Therapy in Neonatal, Pediatric, and Adult Nasal Upper-Airway and Lung Models. Respiratory Care. 2024. doi:10.4187/respcare.11400

BibTeX
@article{DiBlasi2024,
  author = {DiBlasi, Robert M and Engberg, Rebecca J and Poli, Jonathan and Carlin, Kristen E and Kontoudios, Niko and Longest, P Worth and Kajimoto, Masaki},
  title = {Aerosol Delivery Efficiency With High-Flow Nasal Cannula Therapy in Neonatal, Pediatric, and Adult Nasal Upper-Airway and Lung Models},
  journal = {Respiratory Care},
  year = {2024},
  doi = {10.4187/respcare.11400}
}
Kostenlos starten →